These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 18444884)

  • 1. A cytomegalovirus vaccine for transplantation: are we closer?
    Go V; Pollard RB
    J Infect Dis; 2008 Jun; 197(12):1631-3. PubMed ID: 18444884
    [No Abstract]   [Full Text] [Related]  

  • 2. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence.
    Singh N
    Clin Infect Dis; 2005 Mar; 40(5):704-8. PubMed ID: 15714416
    [No Abstract]   [Full Text] [Related]  

  • 3. Counterpoint: prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: the case for prophylaxis.
    Snydman DR
    Clin Infect Dis; 2005 Mar; 40(5):709-12. PubMed ID: 15714417
    [No Abstract]   [Full Text] [Related]  

  • 4. A cytomegalovirus vaccine tames the troll of transplantation.
    Schleiss MR
    Lancet; 2011 Apr; 377(9773):1216-8. PubMed ID: 21481691
    [No Abstract]   [Full Text] [Related]  

  • 5. Cytomegalovirus infection: how to manage it in the immunocompromised transplant recipient?
    Müller GA; Müller CA; Einsele H
    Nephrol Dial Transplant; 1994; 9(1):3-4. PubMed ID: 8177474
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytomegalovirus and varicella-zoster virus vaccines in hematopoietic stem cell transplantation.
    Herr W; Plachter B
    Expert Rev Vaccines; 2009 Aug; 8(8):999-1021. PubMed ID: 19627184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infection in solid-organ transplant recipients.
    Fishman JA
    N Engl J Med; 2007 Dec; 357(25):2601-14. PubMed ID: 18094380
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cytomegalovirus infections in immunosuppressed patients].
    Ruutu P
    Duodecim; 1991; 107(8):629-32. PubMed ID: 1364916
    [No Abstract]   [Full Text] [Related]  

  • 9. Preemptive versus prophylactic approaches in the management of cytomegalovirus disease in solid organ transplant recipients: what we know and what we do not know.
    Meylan PR; Pascual M
    Clin Infect Dis; 2006 Oct; 43(7):881-3. PubMed ID: 16941369
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytomegalovirus prophylaxis strategies in high-risk transplantation.
    Snydman DR
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):20-2. PubMed ID: 7940971
    [No Abstract]   [Full Text] [Related]  

  • 11. Scientific and Regulatory Considerations for Efficacy Studies of Cytomegalovirus Vaccines.
    Krause PR; Roberts J
    J Infect Dis; 2020 Mar; 221(Suppl 1):S103-S108. PubMed ID: 32134485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing Infection by Human Cytomegalovirus.
    Plotkin SA
    J Infect Dis; 2020 Mar; 221(Suppl 1):S123-S127. PubMed ID: 32134484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Status of Vaccine Development Against the Human Cytomegalovirus.
    Plotkin SA; Wang D; Oualim A; Diamond DJ; Kotton CN; Mossman S; Carfi A; Anderson D; Dormitzer PR
    J Infect Dis; 2020 Mar; 221(Suppl 1):S113-S122. PubMed ID: 32134478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prophylaxis of cytomegalovirus infection in the transplant recipient].
    Aguado JM; Lumbreras C; Otero JR
    Med Clin (Barc); 1992 Oct; 99(11):430-4. PubMed ID: 1335103
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevention of cytomegalovirus disease in transplant recipients.
    Pidgeon GB; Bailey RR
    N Z Med J; 1993 Nov; 106(967):468-9. PubMed ID: 8233192
    [No Abstract]   [Full Text] [Related]  

  • 16. The beginning of the end of a long wait for a vaccine against cytomegalovirus.
    Griffiths P
    Rev Med Virol; 2009 May; 19(3):117-9. PubMed ID: 19388047
    [No Abstract]   [Full Text] [Related]  

  • 17. The Development of Therapeutics for the Treatment and Prevention of CMV Disease in the Transplant Population: A Regulatory Perspective.
    Hodowanec AC; Pikis A; Singer ME
    J Infect Dis; 2020 Mar; 221(Suppl 1):S109-S112. PubMed ID: 32134476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The self defense of cytomegalovirus: in this case the lawyer is no fool.
    Geist LJ
    Transplantation; 2008 Jul; 86(2):202-3. PubMed ID: 18645478
    [No Abstract]   [Full Text] [Related]  

  • 19. Optimization of outcomes related to cytomegalovirus in organ transplant recipients.
    Singh N
    Transplantation; 2006 Jul; 82(1):15-6. PubMed ID: 16861935
    [No Abstract]   [Full Text] [Related]  

  • 20. Combination antiviral strategies in managing cytomegalovirus infection.
    Martin M
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):28-30. PubMed ID: 7940973
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.